Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer
Ai Amioka
1), Takayuki Kadoya
1), Satoshi Sueoka
1), Yoshie Kobayashi
1), Shinsuke Sasada
1), Akiko Emi
1), Norio Masumoto
1), Masaoki Ito
1), Koh Nakayama
2), Morihito Okada
1)1) Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima 734-8551,
Japan
2) Oxygen Biology Laboratory, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8510, Japan
Corresponding author：
Takayuki Kadoya, M.D, Ph.D Email: takayukikadoya@gmail.com Tel.: +81-082-257-5869
Fax: +81-082-256-7109
Online Resource 7
RFS in Wnt5a-positive versus -negative breast cancer patients treated with tamoxifen, paclitaxel, cyclophosphamide, epirubicin, and 5-fluorouracil
0%
20%
40%
60%
80%
100%
0 730 1460 2190 2920
P = 0.64
Wnt5a-negative Wnt5a-positive 8-year RFS:
RFS probability (%)
Negative
Positive 14 13 12 8 1
3 2 2 2 0
Number at risk
0 24 48 72 96
100
80 60
40 20
0
Time (months)
100.0% (1.000-1.000) 92.9% (0.794-1.000)
d Epirubicin
0%
20%
40%
60%
80%
100%
0 730 1460 2190 2920
P = 0.74
Wnt5a-negative Wnt5a-positive 8-year RFS:
RFS probability (%)
Negative
Positive 25 23 21 13 2
17 15 13 10 1
Number at risk
0 24 48 72 96
100
80
60
40
20
0
Time (months)
93.3% (0.807-1.000) 91.8% (0.810-1.000)
c Cyclophosphamide
0%
20%
40%
60%
80%
100%
0 730 1460 2190 2920
P = 0.76
Wnt5a-negative Wnt5a-positive 8-year RFS:
RFS probability (%)
Negative
Positive 25 23 21 13 1
16 15 13 10 1
Number at risk
0 24 48 72 96
100 80 60
40 20
0
Time (months)
93.3% (0.807-1.000) 91.8% (0.810-1.000)
b Paclitaxel
0%
20%
40%
60%
80%
100%
0 730 1460 2190 2920
時点
P = 0.12
Wnt5a-negative Wnt5a-positive 8-year RFS:
RFS probability (%)
Negative
Positive 27 23 23 15 2
31 30 29 22 1
Number at risk
0 24 48 72 96
100 80 60
40 20
0
Time (months)
100% (1.000-1.000) 92.3% (0.821-1.000)
a Tamoxifen
